Prospective Double-Blind Evaluation of Topical Adenine Arabinoside in Male Herpes Progenitalis
AUTOR(ES)
Goodman, Edward L.
RESUMO
Thirty-four virologically proven episodes of herpes progenitalis in 32 men were treated in a prospective double-blind study with either adenine arabinoside ointment or an identical-appearing placebo for 7 days. Clinical evaluation and quantitative virological studies were done on days 1, 3, and 8. There was a highly significant correlation between clinical response and quantitative virology. There was no difference in clinical or virological response between drug and control groups. Primary attacks tended to have higher viral excretion over the period of observation. The level of complement-fixing antibody to herpes simplex virus type 2(<1:16 versus ≥1:16) in patients with recurrent disease did not appear to alter the course of viral excretion.
ACESSO AO ARTIGO
http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=429450Documentos Relacionados
- Letter: Griseofulvin therapy in Herpes progenitalis (a double-blind controlled trial).
- Randomised double-blind trial of acyclovir (Zovirax) and adenine arabinoside in herpes simplex amoeboid corneal ulceration.
- A randomised double-blind clinical trial of acyclovir (Zovirax) and adenine arabinoside in herpes simplex corneal ulceration.
- Double-blind clinical trial of topical steroids in anterior uveitis.
- Evaluation of Topical Polyinosinic Acid-Polycytidylic Acid in Treatment of Localized Herpes Zoster in Children with Cancer: a Randomized, Double-Blind Controlled Study